Brief: Mithra End-June Cash Position At EUR 29.3 Mln

Mithra Pharmaceuticals SA

23/09/2022 06:34

Sept 23 (Reuters) - Mithra Pharmaceuticals SA
 MITRA.BR :
    * MITHRA ANNOUNCES 2022 HALF YEAR RESULTS
    * CASH POSITION AT EUR 29.3 MILLION END JUNE 2022
    * REVENUES STANDS AT EUR 11.4 MILLION MOSTLY DRIVEN BY
ESTELLE®
SALES AND A 30% INCREASE IN SALES IN COMPLEX THERAPEUTICS
DIVISION
    * REBITDA FOR THE FIRST HALF 2022 STANDS AT EUR -21.2
MILLION
    * H1 RESEARCH AND DEVELOPMENT EXPENSES (EXCLUDING
DEPRECIATION)
DECREASED BY 31% TO REACH EUR 22.7 MILLION
    * H1 NET LOSS EUR 31.2 MILLION VERSUS LOSS EUR 54.9 MILLION
YEAR
AGO
    * DISCUSSIONS WITH PARTNERS AROUND DONESTA LICENSE AND
SUPPLY
AGREEMENT ARE PROGRESSING, EXPECT NEGOTIATIONS TO ACCELERATE AND
AGREEMENT ANTICIPATED DURING Q4 2022

Source text: https://bit.ly/3DHUDjA
Further company coverage:  MITRA.BR 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))